Regeneron announced that the FDA approved its Veopoz®(pozelimab-bbfg) to treat adult and pediatric patients over one year old with CHAPLE disease, also known as CD55-deficient protein-losing enteropathy. CHAPLE is an extremely rare, life-threatening hereditary immune disease driven by an overactivation of the complement system, and less than 10 people in the US have the disease. Veopoz® is a fully human monoclonal antibody designed to block the activity of complement factor C5.
On the same date, 18 August 2023, Regeneron announced that its 8mg Eylea® (aflibercept) was approved by the FDA to treat wAMD, DME and DR.